Stem Cell Clinic

BioTime CEO Dr. Michael West Presents Product Development Update at World Stem Cell Summit 2012

By Stem Cell Treatment

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, Ph.D. will provide an update today on five products being developed by BioTime and its subsidiaries during a presentation at the World Stem Cell Summit 2012 in West Palm Beach, Florida in the session on Developing Combination Products: Cells, Genes, and Devices at 1:30 pm EST. The presentation will be made available on BioTime's website at http://www.biotimeinc.com.

BioTimes technology platform utilizes pluripotent stem cells that are capable of differentiating into any of the cell types in the body to produce potentially novel first-in-class regenerative therapies for largely unsolved problems in medicine. Using the Companys proprietary ACTCellerateTM technology, BioTime has more than 200 novel and scalable cellular components of the human body.

OTX-CP07 Update

Dr. West will present for the first time information relating to 18 novel and diverse progenitor cell lines capable of differentiating into diverse cartilage and bone types, as well as producing cells with markers of tendon, and brain meningeal tissues. The cartilage progenitor formulation designated OTX-CP07 is being developed by BioTimes subsidiary OrthoCyte Corporation, and is currently beginning the process of animal studies of safety and efficacy for the treatment of intervertebral disc disease. The cartilage, bone, and tendon-producing cell lines may have significant applications in the treatment of orthopedic disorders such as osteoarthritis and low back pain resulting from intervertebral disc disease, while the subset of lines capable of choroid plexus differentiation may have application in the treatment of Alzheimers disease.

Renevia Update

For many of the wide array of cell-based regenerative therapies being developed around the world, the formulation of the cells with a matrix is desired to increase viable and immobilized engraftment. Renevia is designed to be an effective means of transplanting cells in an injectable liquid that can polymerize safely in the body into a tissue construct. Dr. West will report that validation of the analytical methods and manufacturing processes for Renevia are substantially complete. Production of one of Renevias four manufacturing components under Current Good Manufacturing Practice (cGMP) is completed and cGMP production of the remaining three components is scheduled. Clinical trial protocols (three phases) are being drafted and BioTime anticipates that during the first quarter of 2013 a submission of the Renevia Phase I safety trial in humans will be made to the appropriate Spanish Ethics Committee for review and approval. In addition, he will report continued progress on establishing quality management systems for compliance with ISO 13485 (required in the EU for medical devices) and that preliminary review and audit (by an external auditor) is currently scheduled for the first quarter of 2013 with the final ISO audit expected during the second quarter.

PanC-Dx Update

PanC-Dx, being developed by BioTimes subsidiary OncoCyte Corporation, is intended to be a blood-based screening diagnostic for a wide array of solid tumor types. Recent reports of the relative ineffectiveness of mammography in reducing patient death from breast cancer highlight the urgent need for improved tools to accurately detect the disease in its earliest stages. Dr. West will report that OncoCyte has initiated production of monoclonal antibodies to the first seven of its priority cancer markers. In addition, OncoCyte has completed the characterization of over 50 antibodies in order to screen for the subset with greatest specificity for each individual marker. Dynamic testing of the antibodies for use in ELISA and point of care formats are currently underway.

OpRegenand OpRegen-PlusUpdate

Go here to see the original:
BioTime CEO Dr. Michael West Presents Product Development Update at World Stem Cell Summit 2012

Precision StemCell's Neural Reprogrammed Stem Cell Therapy Yields Better-Than-Expected Results for ALS Patients

By Stem Cell Treatment

GULF SHORES, Ala., Dec. 4, 2012 /PRNewswire/ --More than 75 percent of amyotrophic lateral sclerosis (ALS) patients who received neural reprogrammed stem cell therapy have shown a positive response to the procedure. The groundbreaking technique was introduced to the United States this year by Precision StemCell (http://www.precisionstemcell.com), an outpatient imaging and image-guided treatment facility located in Gulf Shores, Ala.

The procedure is performed by Dr. Jason R. Williams, a board-certified radiologist with extensive training in image-guided procedures. Under his care, 14 out of 18 patients diagnosed with ALS, also known as Lou Gehrig's disease, have shown signs of recovery.

"The improvements are mild, with patients reporting improved movement, breathing and speech, but we still have a long way to go," Dr. Williams stated. "Only time will tell how this therapy will affect the patients' long-term prognosis."

In Precision StemCell's neural reprogrammed stem cell therapy, fat-derived stem cells are injected into the spine of the patient. Dr. Williams uses a drug called selegeline, which has been shown to be a pre-inducer of adipose-derived stem cells into neural-like cells. Dr. Williams contends that the therapy is probably one of the largest advances seen in ALS therapy. "Before we started this therapy, I would have been happy just to see the progression of the disease halted, but to see some actual improvement, that was just shocking," he said

The first patient treated with the technique was Frank Orgel who continues to see improvement since his first treatment seven months ago. Eight years ago, Orgel's quality of life had declined to the point that he could not move his left arm or leg, walk or even stand on his own. The therapy has allowed Orgel to stand without assistance, and he continues to work with a physical therapist to regain the ability to walk. Another patient, Dexter Johnson, previously walked with a cane. After the treatment, Johnson has been able to walk without his cane for the majority of the time and he has been able to walk at a much faster pace.

The Precision StemCell center focuses on advanced imaging techniques, which include a 3T Open MRI, a low-dose 64-Slice CT Scanner, ultrasound and fluoroscopy, also known as real-time x-ray. The center is headed by Dr. Williams, who specializes in image-guided procedures, had already been performing magnetic resonance imaging (MRI), computed tomography (CT), ultrasound and fluoroscopy-guided stem cell injections for joint and orthopedic conditions.

In addition to their current work on advanced stem cell harvesting and processing with image-guided stem cell injections, Precision StemCell staff are planning to conduct further research so as to develop even more advanced techniques such as adding gene therapy to the current neural reprogramming platform. "Our therapy techniques not only hold promise for ALS patients, but also for people with other neural-related conditions such as Parkinson's and spinal cord injuries," said Dr. Williams. "There are several candidate genes that we plan to add to the adipose-derived stem cells and study in the mouse model. Though we are happy with our initial progress, our goal is to develop an effective cure."

About Precision StemCell

Located in Gulf Shores, Alabama, Precision StemCell conducts stem cell procedures using advanced imaging techniques, which include an Open 3T MRI, a low-dose 64-Slice CT scanner, ultrasound, and real time x-ray (fluoroscopy). Headed by Jason Williams, MD, a board-certified radiologist with extensive training in image-guided procedures, the facility performs advanced stem cell harvesting and processing with image-guided stem cell injections.

Contact:

More here:
Precision StemCell's Neural Reprogrammed Stem Cell Therapy Yields Better-Than-Expected Results for ALS Patients

Stem Cell Media Interview With Dr. Adrian Harel: Fighting to End ALS, Once and for All

By Stem Cell Treatment

NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwire - Dec 4, 2012) - Sai Rosen of http://www.InvestorStemCell.com (Stem Cell Media, LLC) recently sat down with Dr. Adrian Harel, Chief Executive Officer for Brainstorm Cell Therapeutics Inc. ( OTCQB : BCLI ).Brainstorm Cell Therapeutics Inc. is a biotechnology company developing autologous stem cell therapies for highly debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD) and Spinal Cord Injury. These diseases have limited treatment options and as such represent unmet medical needs.

Dr. Harel has over 30 years' experience in international business development, marketing, clinical development, fund raising and building strategic partnerships. In January 2011, he came to Brainstorm and leveraged all his experience to transform the company from a struggling pre-clinical biotech to the world's leader in clinical stage neurodegenerative treatment for ALS.The company is nearing submission of an ALS Phase II, to be conducted at the renowned Massachusetts General Hospital (MGH).

During his interview, Dr. Harel shared the following information:

Why are you interested in neurodegenerative disorders?

Dr. Harel: "I became fascinated in this area of research while working at Proneuron Biotechnologies.We had created the 'world center' for paralysis.I had the pleasure to work with Christopher Reeve and other clinical leaders.We pioneered these early stage cellular treatments and I was pleased to have played a significant role in regulatory and managing endeavors across multiple channels both internal and external."

What brought you to Brainstorm?

Dr. Harel: "I have spent my whole life helping others, working with teams that are inspired to find solutions to difficult biological problems with the end goal to ease the burden of suffering.ALS is in my opinion the worst of the worst when considering unmet neurodegenerative diseases.I believe our data from the ALS Phase I is showing measurable improvements in key areas of those afflicted and may be proven to be a treatment for ALS."

What is the credit market like?

Dr. Harel: "It has been difficult to engage in terms that are not burdensome to goals. It is a fine line to ensure solvency, manage dilution and move our clinical trials forward as expeditiously as possible. I was able to arrange favorable terms early this summer and closed in July on a $5.7 million Public Offering.We have been successful with securing non-dilutive grants.Since coming to Brainstorm in January, I have raised over $10 million."

What is next for Brainstorm?

Excerpt from:
Stem Cell Media Interview With Dr. Adrian Harel: Fighting to End ALS, Once and for All

NeoStem to Present at Multiple Conferences in December

By Uncategorized

NEW YORK, Dec. 3, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple conferences in December.

World Stem Cell Summit

RedChip Small-Cap Equities Virtual Conference

Cell Therapy Manufacturing (Informa Life Sciences' 3rd Annual VIC Congress 2012)

American Society of Hematology Annual Meeting and Exposition ("ASH")

NeoStem's abstract on VSELTM Technology titled "A Lin-CD45-CD34+ Population of Extracellular Vesicles in Human Blood That Mimics Very Small Embryonic-Like Stem Cells (VSELs) by Flow Cytometry" has been selected for publication online in December in conjunction with the ASH Annual Meeting and Exposition, December 8-11, 2012. The abstract will be available at http://bloodjournal.hematologylibrary.org/site/misc/ASH_Meeting_Abstracts_Info.xhtml.

About NeoStem, Inc.

NeoStem, continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift occurring in medicine. We anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, PCT, with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe that, with our expertise and research capabilities and collaborations, we will achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert to create a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we are well positioned to succeed.

For more information, please visit http://www.neostem.com.

See the article here:
NeoStem to Present at Multiple Conferences in December

VistaGen Therapeutics Becomes Member of Centre for Commercialization of Regenerative Medicine (CCRM) Consortium

By Stem Cell Treatment

SOUTH SAN FRANCISCO, CA--(Marketwire - Dec 3, 2012) - VistaGen Therapeutics, Inc. ( OTCBB : VSTA ), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, has formalized its membership in the Toronto-based Centre for Commercialization of Regenerative Medicine's (CCRM) Industry Consortium.

"VistaGen's membership reflects our strong association with CCRM and its core programs and objectives, both directly and through our strategic relationships with Dr. Gordon Keller and the University Health Network (UHN).Our long-term sponsored research agreement with Dr. Keller, UHN and UHN's McEwen Centre for Regenerative Medicine offers both a solid foundation and unique opportunities for expanding the commercial applications of our Human Clinical Trials in a Test Tube platform by building multi-party collaborations with CCRM and members of its Industry Consortium," says Shawn Singh, VistaGen CEO. "These collaborations have the potential to transform medicine and accelerate significant advances in human health and wellness that stem cell technologies and regenerative medicine promise."

"Even before VistaGen joined CCRM's Industry Consortium it was active in the Toronto regenerative medicine community and advising us as we prepared to launch in 2011," explains Dr. Michael May, CEO of the Centre for Commercialization of Regenerative Medicine. "I'm confident that our relationship will grow stronger with VistaGen as a formal partner and I look forward to us working closely together on projects that will accelerate drug discovery and benefit patients."

CCRM is a not-for-profit, public-private consortium funded by the Government of Canada, six Ontario-based institutional partners and more than 20 companies representing the key sectors of the regenerative medicine industry. CCRM supports the development of foundational technologies that accelerate the commercialization of stem cell- and biomaterials-based products and therapies. Other members of CCRM's Industry Consortium include such leading global companies as Pfizer, GE Healthcare and Lonza.

The industry leaders that comprise the CCRM consortium benefit from proprietary access to certain licensing opportunities, academic rates on fee-for-service contracts at CCRM and opportunities to participate in large collaborative projects, among other advantages.VistaGen is especially well positioned through its existing relationships with key members.

Gordon Keller, Ph.D. is Director of the McEwen Centre for Regenerative Medicine at UHN. A CCRM partner, the McEwen Centre is a world-renowned centre for stem cell biology and regenerative medicine and a world-class stem cell research facility. He is also a Professor at the University of Toronto in the Department of Medical Biophysics and Senior Scientist of the Ontario Cancer Institute in Toronto.Dr. Keller's lab is one of the world leaders in successfully applying principles from the study of developmental biology of many animal systems to the differentiation of pluripotent stem cell systems, resulting in reproducible, high-yield production of human heart, liver, blood and vascular cells.The results and procedures developed in Dr. Keller's lab are often quoted and used by academic scientists worldwide.

UHN, a major landmark in Canada's healthcare system, is one of the world's largest research hospitals, with major research in transplantation, cardiology, neurosciences, oncology, surgical innovation, infectious diseases and genomic medicine. Providing care to the community for more than two centuries, UHN brings together the talent and resources needed to achieve global impact and provide exemplary patient care, research and education.

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube, with modern medicinal chemistry to generate new chemical variants (Drug Rescue Variants) of once-promising small-molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories after substantial investment and development due to heart or liver toxicity or metabolism issues. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

Additionally, VistaGen's small molecule drug candidate, AV-101, is completing Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide.To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

View post:
VistaGen Therapeutics Becomes Member of Centre for Commercialization of Regenerative Medicine (CCRM) Consortium

Stem cell-derived dopaminergic neurons rescue motor defects in Parkinsonian monkeys

By Stem Cell Treatment

ScienceDaily (Dec. 3, 2012) Researchers have derived dopaminergic neurons from bone marrow stem cells in monkeys.

Parkinson's disease is a degenerative disorder of the central nervous system that is characterized by tremors, rigidity, slowness of movement, and difficulty walking. It is caused by loss of the neurons that produce the neurotransmitter dopamine (known as dopaminergic neurons). One of the primary goals in Parkinson's disease research is to develop a replacement for dopaminergic neurons.

In a new study, researchers led by Takuya Hayashi at the RIKEN Center for Molecular Imaging Science in Kobe, Japan, derived dopaminergic neurons from bone marrow stem cells in monkeys. The cells were retrieved during a standard bone marrow aspiration and then treated with growth factors that directed the stem cells to become dopaminergic neurons. The monkeys that donated the stem cells were treated with a chemical to induce Parkinson's disease and then received a transplant of the new dopaminergic neurons that had been derived from their own bone marrow stem cells. Monkeys that received the transplant showed significant improvement in motor defects.

This study demonstrates that dopaminergic neurons derived from adult bone marrow stem cells can be safely used to improve motor function in Parkinson's disease in monkeys.

The research is published in the Journal of Clinical Investigation.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Journal of Clinical Investigation.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Read more from the original source:
Stem cell-derived dopaminergic neurons rescue motor defects in Parkinsonian monkeys

UA professor furthers stem cell research

By Stem Cell Treatment

By SARAH-JAYNE SIMON Published December 2, 2012 at 9:46pm Updated December 2, 2012 at 9:46pm

A UA professor has been recognized for his work as a pioneer in stem cell banking.

David Harris, professor of immunobiology, was awarded the Arizona BioIndustry Association 2012 award for 20 Years of Discovery and Innovation.

Harris recognition is the culmination of decades of work in the field of stem cell research. Harris came to the UA 23 years ago from the University of North Carolina and said he was interested in improving the bone marrow transplant process. As a result, he began to use a process called cord blood banking. In 1991, Harris became the first person to bank stem cells for future use, which includes saving them for future treatments.

Its nice to end up being recognized for something that you have worked on for a long time, Harris said. Taking something and making it important for everyday life for people to improve their life is amazing. From starting with animal models and moving to human beings is huge; its nice to see it go from one point to another.

Harris said he banked stem cells for future use by preserving his first childs cord blood stem cells. A year later, Harris founded the Arizona Cord Blood Bank, which later became the Cord Blood Registry. Harris continues to serve as Chief Science Officer of the company, which is the largest cord blood stem cell bank in the world.

I had always been interested in science and particularly in biological sciences, Harris said. I was quite interested in sciences in general and got my degree in immunology. The general interest in science has always been there since an early age. Stem cells is the one I find to be most interesting these days.

The Arizona BioIndustry Association is made up of businesses as well as research and government organizations and those associated with other professions involved in biosciences. The annual Arizona BioIndustry Association Awards was held at the Phoenix Convention Center this year.

In the late 1980s, it was discovered that you could find left over blood cells in the umbilical cord after the baby was born, Harris said. Early on, we realized this was going to be an important source of stem cell transplant. After 15 years, we realized those stem cells present in umbilical cords had gone from the research stage into the treatment process.

Harris said that the support from the UA community during the progress of his reasearch is what enabled him to come this far.

Read the original here:
UA professor furthers stem cell research

Seeing results from stem cell treatment

By Stem Cell Treatment

Christine Wood/Photo

Alison Johnstone kisses and hugs her grandson Rylan who is showing signs of improvement after receiving stem cell treatments in China last month.

Christine Wood/Staff Writer

Since returning home from having stem cell treatments in China last month, five-year-old Rylan Johnstone has taken his first unaided steps, given his first hug, spoken his first complete sentence and shown his first reaction to light much to the delight of his family.

We are absolutely overjoyed with the changes weve noticed already, said Rylans grandma Alison. Even if thats all that happens, it was definitely worth it to go, but I think there are more changes to come.

The family spent nearly a year fundraising more than $34,000 for the trip to China to have the stem cell treatments done in the hope that Rylan, who is blind and autistic, would gain some sight and mobility and benefit from reduced autism symptoms.

It seems much of that wish list has come true just weeks after returning from China, and the stem cells will keep working, Alison said.

The stem cell injections in his eyes should keep working for at least six months, she said, noting one report from a parent showed a child gaining sight a year after the stem cell treatments.

Rylan seems to squint now when a bright light is put before him, and although he cant communicate whats happening, the Johnstones are hopeful hell show more signs of sight in the weeks to come.

One of the best moments for Alison was when she got her first hug from her grandson, shortly after returning home.

Follow this link:
Seeing results from stem cell treatment

Stem Cells Provide Hope For A Potential Treatment of Glaucoma

By Stem Cell Treatment

Editor's Choice Main Category: Stem Cell Research Also Included In: Eye Health / Blindness Article Date: 04 Dec 2012 - 0:00 PST

Current ratings for: Stem Cells Provide Hope For A Potential Treatment of Glaucoma

Irreversible blindness is most often caused by glaucoma in today's world. About 1 in 50 people over the age of 40 in the UK struggle with glaucoma. The odds increase for people aged 75 years and older, affecting 1 in 10. Since the condition is age-related, it is becoming more prevalent as the UK population gets older.

Glaucoma is often an insidious, progressive condition which results in harm to the optic nerve. Once the person realizes that damage has been done, some of loss of vision has already taken place.

Risk factors associated with glaucoma include:

The team experimented with a potential treatment that involves using the patient's own stem cells. Professor Raisman was able to halve the loss of optic nerve fibers caused by raised eye pressure by transferring a few olfactory ensheathing cells into the area of the optic nerve. This also caused reduced the harm to the optic nerve tissue.

The progression of glaucoma can be stopped by a few treatments, including medication and eye surgery to lower the pressure in the eye. One previous report indicated that eye drops containing nerve growth factor could halt glaucoma symptoms.

However, no therapies can treat vision loss, and unfortunately, the progression towards blindness cannot be prevented in a significant number of people.

This study increases the chance that a simple surgical procedure, using cells taken from the patient, could guide scientists to a future technique that could stop the horrible outcome of glaucoma, Professor Raisman said, even though the procedure is still at the experimental stage.

Professor Khaw added:

More:
Stem Cells Provide Hope For A Potential Treatment of Glaucoma

Autologous Cell Therapy Market expected to reach $2.2 billion by 2017, growing at a CAGR of 21% : MarketsandMarkets

By Uncategorized

Autologous Cell Therapy Market reserach report gives a detailed analysis about state of the art of both autologous stem cell and non-stem cell treatments. It includes the current advances and applications of the technology and trends in terms of market size and growth of autologous cellular therapies in medical treatments globally.

(PRWEB) November 30, 2012

Browse ACT market research data tables/figures spread through 111 slides and in-depth TOC on Autologous Cell Therapy (ACT) Market (2012 - 2017).

http://www.marketsandmarkets.com/Market-Reports/autologous-cell-therapy-market-837.html

Early buyers will receive 10% customization on reports.

There is a wide market potential and favorable landscape for adoption across many geographical locations of the world. During the forecast period, these technologies are expected to revolutionize the area of bio-pharma and personalized medicine. High incidence and lack of effective treatment for several diseases will drive the ACT technology in developed and developing nations.

Investment activities, for past five years are actively held in research and developments, attracting interests of cell therapy industry firms, medical centers and academic institutions. ACT potential can be demonstrated by mergers, collaborations, acquisitions and partnerships that happened actively between the ACT technology developing companies in past three years. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market.

The global market for ACT is valued around $650 million by 2011 with a CAGR of 21%. Several products and technologies of ACT are in pipeline which is expected to hit the market during the forecast period, which will result in increased growth rate.

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services.

Read the original post:
Autologous Cell Therapy Market expected to reach $2.2 billion by 2017, growing at a CAGR of 21% : MarketsandMarkets

→←